

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.02.26.~2024.03.03.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 69건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06106308	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Drug: Onvansertib Drug: FOLFIRI Drug: Bevacizumab Drug: FOLFOX	Cardiff Oncology Pfizer	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06106308
NCT05776277	Ittamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury	Biological: Ittamiocel Other: Placebo	Cook MyoSite	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05776277
NCT06277219	A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)	Drug: LAT010 Drug: LAT010 + ICI	Latticon Antibody Therapeutics, Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06277219
NCT06249191	Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration and Biopsy Procedure: Computed Tomography Drug: Cyclophosphamide Drug: Doxorubicin Procedure: Echocardiography Drug: Etoposide Procedure: Magnetic Resonance Imaging Biological: Mosunetuzumab Procedure: Multigated Acquisition Scan Procedure: Positron Emission Tomography Drug: Prednisone Drug: Vincristine	OHSU Knight Cancer Institute Genentech, Inc. Oregon Health and Science University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06249191
NCT06245915	AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)	Biological: AB-2100	Arsenal Biosciences, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06245915
NCT06105021	Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor	Drug: AFNT-211	Affini-T Therapeutics, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06105021
NCT06096038	Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC	Drug: Cyclophosphamide Drug: Fludarabine Biological: Cell Therapy	UNC Lineberger Comprehensive Cancer Center Bellicum Pharmaceuticals University Cancer Research Fund at Lineberger Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06096038
NCT06090864	ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells	Drug: Chemotherapy Biological: Cell infusion	UNC Lineberger Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06090864
NCT06085729	Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)	Drug: ADI-PEG 20 Drug: Cabazitaxel Drug: Carboplatin	M.D. Anderson Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06085729
NCT06083857	PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer	Drug: Amivantamab Drug: Tepotinib	M.D. Anderson Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06083857

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 미국 69건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06026657	Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβ Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer	Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Gemcitabine Procedure: Magnetic Resonance Imaging Biological: Naxitamab Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells	Margaret Gatti-Mays Ohio State University Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06026657
NCT05956821	Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age	Drug: SIACI of cetuximab and bevacizumab	University of Miami	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05956821
NCT05936229	Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	Biological: Interferon Beta-1A Procedure: X-Ray Imaging Procedure: Echocardiography Procedure: Multigated Acquisition Scan Procedure: Computed Tomography Procedure: Positron Emission Tomography Procedure: Lumbar Puncture Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Biospecimen Collection Procedure: Biopsy	Fred Hutchinson Cancer Center Faron Pharmaceuticals Ltd	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05936229
NCT06157892	A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors	Drug: disitamab vedotin Drug: tucatinib	Seagen Inc. RemeGen Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06157892
NCT06281678	A Study of IBI363 in Subjects With Advanced Solid Malignancies	Drug: IBI363	Innovent Biologics (Suzhou) Co. Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06281678
NCT06263153	Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy	Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Durvalumab Drug: Futibatinib Procedure: Magnetic Resonance Imaging Procedure: Radical Cystectomy	Yuanquan Yang Gateway for Cancer Research Ohio State University Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06263153
NCT06258304	A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Drug: GIGA-564	GigaGen, Inc. National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06258304
NCT06252675	Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma	Biological: Obinutuzumab Biological: Glofitamab Drug: Pirtobrutinib Procedure: Tumor Imaging Procedure: Biospecimen Collection Device: ClonoSeq Assay Procedure: Bone Marrow Biopsy	C. Babis Andreadis Eli Lilly and Company Genentech, Inc. Adaptive Biotechnologies University of California, San Francisco	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06252675
NCT06251544	TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer	Genetic: HTR2 T Cells	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital Research Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06251544
NCT06238479	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Drug: LY4101174	Eli Lilly and Company Loxo Oncology, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06238479
NCT06224673	ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer	Drug: ARX788 Procedure: Computed Tomography (CT) Procedure: Biospecimen Collection	Laura Huppert, MD, BA Ambrx, Inc. University of California, San Francisco	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06224673

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 미국 69건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06203912	Donor Immune Cells (TGFβ NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration and Biopsy Drug: Cyclophosphamide Drug: Dexamethasone Procedure: Echocardiography Biological: Isatuximab Other: Questionnaire Administration Biological: Universal Donor Expanded TGF-β-imprinted NK Cells	Elvira Umyarova Sanofi Ohio State University Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06203912
NCT06193486	Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC	Biological: MSGV1-PSCA-8T28Z Drug: Fludarabine Drug: Cyclophosphamide	H. Lee Moffitt Cancer Center and Research Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06193486
NCT06186401	Anti-EGFR/IL-13Rα2 CAR (E-SYNC) T Cells	Biological: E-SYNC T Cells Drug: Cyclophosphamide (non-investigational) Drug: Fludarabine (non-investigational) Procedure: Leukapheresis Procedure: Surgical resection	Hideho Okada, MD, PhD California Institute for Regenerative Medicine (CIRM) National Cancer Institute (NCI) University of California, San Francisco	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06186401
NCT06173778	Semaglutide for Post-Smoking Cessation Weight Management	Drug: semaglutide 2.4mg Drug: Placebo Drug: Nicotine Replacement Therapy (NRT, nicotine patch) Behavioral: Brief Smoking Cessation Counseling	The University of Texas Health Science Center, Houston	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06173778
NCT06169397	An Open-label Extension Study of XTMAb-16 in Patients With Pulmonary Sarcoidosis	Drug: XTMAb-16	Xentria, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06169397
NCT06094842	Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer	Drug: Bendamustine Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Scan Procedure: Bridge Therapy Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Procedure: Leukapheresis Procedure: Multigated Acquisition Scan Biological: T-cell Receptor-engineered T-cells Procedure: X-Ray Imaging	Fred Hutchinson Cancer Center Bristol-Myers Squibb	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06094842
NCT06072612	Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.	Biological: SV-BR-1-GM Drug: Cyclophosphamide Drug: Interferon infiltration of the inoculation site Drug: Retifanlimab Drug: Treatment of Physician's Choice	BriaCell Therapeutics Corporation	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06072612
NCT06058663	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma	Procedure: Angiography Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Durvalumab Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Biological: Tremelimumab Procedure: Yttrium-90 Microsphere Radioembolization	Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06058663
NCT06048133	Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers	Drug: Gemcitabine Drug: Cisplatin Drug: Zimberelimab Drug: Quemliclustat	Nataliya Uboha Arcus Biosciences, Inc. Gilead Sciences University of Wisconsin, Madison Big Ten Cancer Research Consortium	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06048133

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 미국 69건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06017297	Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: Tremelimumab Drug: Gemcitabine Drug: Cisplatin Procedure: Surgical Resection	Georgetown University AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06017297
NCT06001658	Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers	Drug: Gemcitabine Drug: Cisplatin Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06001658
NCT05960578	Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study	Drug: Apalutamide Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Golimumab Procedure: Magnetic Resonance Imaging Procedure: PSMA PET Scan	University of Washington Janssen Scientific Affairs, LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05960578
NCT05864534	Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma	Drug: Balstilimab Drug: Botensilimab Drug: Liposomal Doxorubicin Device: SonoCloud-9 (SC-9)	Northwestern University Agenus Inc. CarThera	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05864534
NCT05849389	Vosoritide for Short Stature in Turner Syndrome	Drug: Vosoritide	Roopa Kanakatti Shankar, MBBS, MS Children's National Research Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05849389
NCT05757843	Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	Diagnostic Test: Signatera ctDNA test Drug: Durvalumab	Indiana University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05757843
NCT05717140	Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung	Biological: Aerosol Sargramostim Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Other: Medical Device Usage and Evaluation Biological: Nivolumab	Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05717140
NCT05676749	C-TIL051 in Non-Small Cell Lung Cancer	Biological: C-TIL051	AbelZeta, Inc. Nektar Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05676749
NCT05632315	PMT for MDRO Decolonization	Drug: PMT	University of Pennsylvania	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05632315
NCT05485155	Zemaira Eosinophilic Esophagitis Pilot Study	Drug: Alpha-proteinase inhibitor	Children's Hospital Medical Center, Cincinnati CSL Behring National Institutes of Health (NIH)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05485155
NCT05424003	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	Drug: Semaglutide Pen Injector Drug: Placebo	Virginia Commonwealth University Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05424003
NCT05067595	Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease	Procedure: Colonoscopy Biological: Fecal Microbiota Transplantation Dietary Supplement: Nutritional Supplementation Other: Survey Administration	Fred Hutchinson Cancer Center National Heart, Lung, and Blood Institute (NHLBI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05067595

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 미국 69건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04876248	Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant	Biological: Belantamab Mafodotin Drug: Lenalidomide	Roswell Park Cancer Institute GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04876248
NCT04715191	Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors	Genetic: CARE T cells Drug: Cytoxin Drug: Fludara	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04715191
NCT04093323	Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04093323
NCT03508479	Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection	Biological: RG-HRV16	University of North Carolina, Chapel Hill	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03508479
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03463239
NCT06272695	Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab	Biological: Volagidemab	REMD Biotherapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06272695
NCT06239220	PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC	Biological: PD-L1 t-haNK Drug: Cetuximab Biological: N-803	Glenn J. Hanna ImmunityBio, Inc. Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06239220
NCT06120504	A Safety Study of SGN-35T in Adults With Advanced Cancers	Drug: SGN-35T	Seagen Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06120504
NCT06096779	A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis	Drug: Atezolizumab Drug: Bevacizumab	Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06096779
NCT05951777	Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury	Biological: Autologous HB-adMSCs Drug: Normal Saline	Hope Biosciences The University of Texas Health Science Center, Houston	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05951777
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Biological: Bevacizumab Biological: Pembrolizumab Other: Quality-of-Life Assessment Other: Questionnaire Administration	Roswell Park Cancer Institute National Cancer Institute (NCI) Merck Sharp & Dohme LLC Celldex Therapeutics	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05231122
NCT04952584	Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas	Biological: CD30.CAR-EBVST cells	Baylor College of Medicine The Methodist Hospital Research Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04952584
NCT06282575	Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer	Drug: Zanidatamab Drug: Cisplatin Drug: Gemcitabine Drug: Pembrolizumab Drug: Durvalumab	Jazz Pharmaceuticals	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06282575

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 미국 69건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06145035	Single or Repeated Intravenous Administration of umbilical Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy	Biological: umbilical cord-derived mesenchymal stromal cells (UC-MSCs)	Roberto Bolli University of Miami University of Texas United States Department of Defense University of Louisville	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06145035
NCT06056102	CAR-T Cell Therapy for Desensitization in Kidney Transplantation	Drug: Cyclophosphamide Biological: CART-BCMA Biological: huCART19 Drug: Fludarabine	National Institute of Allergy and Infectious Diseases (NIAID) University of Pennsylvania Clinical Cell and Vaccine Production Facility (CVPF)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06056102
NCT05866562	Dupilumab in the Treatment of Pediatric Alopecia Areata	Drug: Dupilumab Drug: Placebo	Icahn School of Medicine at Mount Sinai	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05866562
NCT05874193	A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma	Drug: Belantamab mafodotin	Cristiana Costa Chase, DO Duke University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05874193
NCT06051695	A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression	Biological: A2B694 Diagnostic Test: xT CDx with HLA-LOH Assay	A2 Biotherapeutics Inc. Tempus AI	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06051695
NCT06220201	A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis	Drug: CC-97540 Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06220201
NCT06075745	Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates	Drug: CMV-MVA Triplex Drug: Placebo for CMV-MVA Triplex	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06075745
NCT06008093	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients	Drug: Durvalumab Drug: Tremelimumab Drug: Pemetrexed Drug: Pembrolizumab Drug: Carboplatin Drug: Cisplatin	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06008093
NCT05973487	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Biological: TSC-204-A0201 Biological: TSC-204-C0702 Biological: TSC-200-A0201 Biological: TSC-204-A0201 + TSC-204-C0702 Biological: TSC-204-A0201 + TSC-200-A0201 Biological: TSC-204-C0702 + TSC-200-A0201 Biological: TSC-204-A0201 + TSC-203-A0201 Biological: TSC-204-C0702 + TSC-203-A0201 Biological: TSC-200-A0201 + TSC-203-A0201	TScan Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05973487
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372
NCT06275360	Repositioning Immunotherapy in VetArans With Lung Cancer	Drug: Nivolumab	VA Office of Research and Development	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06275360

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 미국 69건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05948566	Strategy for Improving Stroke Treatment Response	Biological: TS23	Translational Sciences, Inc. University of Cincinnati National Institutes for Neurologic Disorders and Stroke (NINDS) Medical University of South Carolina University of Arizona	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05948566
NCT06120140	Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib	Drug: Amivantamab Drug: Lazertinib Drug: Doxycycline Drug: Minocycline Drug: Clindamycin Drug: Chlorhexidine Other: Noncomedogenic skin moisturizer	Janssen Research & Development, LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06120140
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079359

○ 영국 8건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05646199	Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)	Drug: Metformin Drug: Semaglutide Injectable Product	University of Hull	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05646199
NCT06283212	A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome	Drug: ETX101	Encoded Therapeutics	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06283212
NCT06286709	FAecal Microbiota Transplantation in primary sclerosing cholangitis	Biological: Faecal Microbiota Transplant Other: FMT Placebo	University of Birmingham PSC Support Life Arc	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06286709
NCT06220201	A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis	Drug: CC-97540 Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06220201
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079359
NCT05718297	Brigatinib Post Definitive Chemoradiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718297
NCT05056220	Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites	Drug: Human albumin Drug: sodium chloride	Aleksander Krag EASL - CLIF Consortium Odense University Hospital	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05056220

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 프랑스 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05654753	The Efficacy of Fecal Microbiota Transplantation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment	Drug: active FMT Drug: Placebo	Assistance Publique - Hôpital de Paris Fondation Arthritis & Clarins Worldwide 2016	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05654753
NCT06116578	Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab	Drug: Pembrolizumab Drug: Pembrolizumab and Olaparib Drug: Pembrolizumab adjuvant	Gustave Roussy, Cancer Campus, Grand Paris Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06116578
NCT06031259	Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment	Drug: Idursulfase-IT Drug: Elaprase	Takeda	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06031259
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718297
NCT06220201	A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis	Drug: CC-97540 Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06220201
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079359

○ 독일 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06218069	Immuno-pet iMaging responses administered Immune checkpoint inhibitor	Drug: Sasanlimab Radiation: non-ablative radiotherapy Drug: [89Zr]Zr-crefmirsimab berdoxam	Radboud University Medical Center Pfizer ImaginAb, Inc. University Hospital Tuebingen	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06218069
NCT06189157	MB-CART19.1 in Refractory SLE	Biological: MB-CART19.1	Miltenyi Biomedicine GmbH	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06189157
NCT06220201	A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis	Drug: CC-97540 Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06220201
NCT05056220	Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites	Drug: Human albumin Drug: sodium chloride	Aleksander Krag EASL - CLIF Consortium Odense University Hospital	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05056220
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079359

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 중국 24건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06288373	Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC	Drug: Camrelizumab Drug: Cisplatin Drug: Nab paclitaxel Procedure: Radical surgery Radiation: external beam radiation therapy (EBRT) + brachytherapy	Tongji Hospital Southwest Hospital, China Women Hospital, School of Medicine, Zhejiang University Anhui Provincial Cancer Hospital Sichuan Cancer Hospital and Research Institute Qilu Hospital of Shandong University Beijing Friendship Hospital Tianjin Medical University General Hospital West China Second University Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Xiangya Hospital of Central South University Gansu Provincial Maternal and Child Health Care Hospital Zhejiang Cancer Hospital Shengjing Hospital	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06288373
NCT06239298	A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor	Drug: ZG005 Powder for Injection Drug: Donafenib Tosilate Tablets	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06239298
NCT06223841	A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors	Drug: IAP0971	SUNHO(China)BioPharmaceutical I CO., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06223841
NCT06208410	A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors	Drug: JS105 Drug: Fulvestrant injection Drug: Dalpiciclib Isetionate Tablets Drug: Toripalimab Injection Drug: Paclitaxel for Injection (Albumin Bound) Drug: Fluzoparib Capsules Drug: Pyrotinib Maleate Tablets Drug: Capecitabine Tablets	Risen (Suzhou) Pharma Tech Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06208410
NCT06114511	A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer	Drug: BL-M07D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06114511
NCT06031584	A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors	Drug: BL-M07D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06031584
NCT06289894	A Study of BRY805 in Participants With Advanced Solid Tumors	Drug: BRY805 injection	BioRay Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06289894
NCT06257966	A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin	Drug: Exendin-4 Fc fusion protein injection(1.2mg) Drug: Exendin-4 Fc fusion protein injection(2.4mg) Drug: Dulaglutide Drug: Metformin	Beijing Dongfang Biotech Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06257966
NCT06281405	CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer	Drug: PD-1 antibody Drug: Capecitabine Radiation: Short-course radiotherapy	Fudan University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06281405

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 중국 24건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06289751	Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer	Drug: Cadonilimab Drug: Paclitaxel-albumin Drug: Cisplatin Procedure: Extrafascial hysterectomy	Tongji Hospital The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) Women Hospital, School of Medicine, Zhejiang University Southwest Hospital, China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Sichuan Cancer Hospital and Research Institute Qilu Hospital of Shandong University Beijing Friendship Hospital Tianjin Medical University West China Second University Hospital Xiangya Hospital of Central South University Gansu Provincial Maternal and Child Health Care Hospital Zhejiang Cancer Hospital Shengjing Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06289751
NCT06289062	Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer	Drug: Camrelizumab Drug: Cisplatin Drug: Nab paclitaxel Procedure: biopsy	Tongji Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Women Hospital, School of Medicine, Zhejiang University Third Military Medical University Beijing Friendship Hospital Sichuan Cancer Hospital and Research Institute Tianjin Medical University West China Second University Hospital Xiangya Hospital of Central South University Qilu Hospital of Shandong University Gansu Cancer Hospital Zhejiang Cancer Hospital Shengjing Hospital Anhui Provincial Cancer Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06289062
NCT06288360	Neoadjuvant Immunochemotherapy in PD-L1-negative LACC	Drug: Camrelizumab Drug: Paclitaxel-albumin Drug: Cisplatin Procedure: radical surgery	Tongji Hospital Southwest Hospital, China Women Hospital, School of Medicine, Zhejiang University Anhui Provincial Cancer Hospital Sichuan Cancer Hospital and Research Institute Gansu Provincial Maternal and Child Health Care Hospital Beijing Friendship Hospital Tianjin Medical University General Hospital Xiangya Hospital of Central South University West China Second University Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Zhejiang Cancer Hospital Shengjing Hospital Qilu Hospital of Shandong University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06288360
NCT06282445	Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer	Drug: Adebrelimab Drug: Oxaliplatin Drug: Capecitabine Drug: Bevacizumab	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06282445

해외 바이오의약품 임상 현황 ('24년 2월 5주)

한국바이오의약품협회, 2024.03.05.

○ 중국 24건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06254014	A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients	Drug: Exendin-4 Fc fusion protein injection Drug: Placebo	Beijing Dongfang Biotech Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06254014
NCT06251180	Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma	Drug: Rocbrutinib Biological: Rituximab Drug: Cyclophosphamide Drug: doxorubicin Drug: Vincristin Drug: Prednisone	Guangzhou Lupeng Pharmaceutical Company LTD.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06251180
NCT06235086	Phase 3 Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus	Drug: TG103 Drug: Dulaglutide	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06235086
NCT06232902	A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avatin® in Healthy Volunteers	Drug: QL1101 Drug: Avastin®	Qilu Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06232902
NCT06210334	HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)	Drug: Tislelizumab Drug: Lenvatinib	Li Xiao Wei Eastern Hepatobiliary Surgery Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06210334
NCT06204094	Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer	Radiation: node-sparing short-course radiotherapy Drug: Sintilimab Drug: Capecitabine Drug: Oxaliplatin Procedure: TME surgery Procedure: watch and wait	Jinhua Central Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06204094
NCT06143748	Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)	Drug: Cadonilimab Drug: Paclitaxel and cisplatin Radiation: intensity-modulated radiotherapy	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06143748
NCT06291961	A Safety and Efficacy Study Evaluating CS-101 in Subjects With β -Thalassemia Major	Genetic: CS-101 injection	CorrectSequence Therapeutics Co., Ltd	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06291961
NCT06205862	Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)	Procedure: fecal microbiota transplantation	Shenzhen Hospital of Southern Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06205862
NCT06221748	DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy	Drug: Disitamab Vedotin Injection Drug: Cadonilimab Injection Drug: Paclitaxel Injection	RemeGen Co., Ltd.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06221748
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079359

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05485766	Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer	Drug: Pembrolizumab Drug: Paclitaxel Drug: Carboplatin Drug: Olaparib Procedure: Definitive Surgery	Okayama University Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05485766
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372